|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||10.76 - 11.36|
|52 Week Range||5.01 - 22.67|
|Beta (3Y Monthly)||2.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The university struck a deal with Barings to sell some of its U.S. rights for a drug used to treat dangerously low blood pressure.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 0.00% and -1.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
On GW Pharmaceuticals' (GWPH) second-quarter conference call, investor focus will be on the initial sales uptick of its newly launched anti-epileptic drug Epidiolex.
On CannTrust's (CTST) second-quarter earnings call, investor focus will be on the company's efforts to resolve matters regarding the non-compliant report issued by Health Canada.
The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.
La Jolla Pharmaceutical (LJPC) needs investors to pay close attention to the stock based on moves in the options market lately.
If you own shares in La Jolla Pharmaceutical Company (NASDAQ:LJPC) then it's worth thinking about how it contributes...
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of $1.17. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is not uncommon among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NCSM. The closing price on Friday was 4.1% off the 52-week low of $3.93 and 355% from the 52-week high of $18.6.
In 2012 George Tidmarsh was appointed CEO of La Jolla Pharmaceutical Company (NASDAQ:LJPC). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ofRead More...
Investors need to pay close attention to La Jolla Pharmaceutical (LJPC) stock based on the movements in the options market lately.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 4) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
La Jolla Pharmaceutical Company (NASDAQ: LJPC ) reported net 2018 sales of $10.1 million for the septic shock treatment Giapreza this week and announced 2019 sales guidance of $24 million to $28 million ...
La Jolla's share price fell to $5.64 by 2:34 pm, down from its close of $10.52 on Friday, after the company said it expects sales of low blood pressure drug Giapreza to hit $24 million-$28 million in 2019, roughly half of what analysts had projected. The pharmaceutical company's stock has been trending downward since late September, when it was trading at more than $22. La Jolla reported a 20% increase during the fourth quarter in sales of Giapreza, first launched in March, with sales of the drug, used to increase blood pressure in patients suffering from septic or distributive shock.
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]